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Introduction {#ehf212693-sec-0001}
============

Hypocalcaemic cardiomyopathy is considered to be a very rare cause of heart failure with reduced left ventricular (LV) ejection fraction (EF). This article reports the first two cases of hypocalcaemic cardiomyopathy that have been described in the Czech Republic. A description of the first case was published in the regional journal of the *Czech Society of Cardiology* 'Cor et Vasa'.[^1^](#ehf212693-bib-0001){ref-type="ref"} However, because this case clearly describes the typical course of hypocalcaemic cardiomyopathy, we are also presenting it in this article. The second case in this article is being described for the first time. In addition, this article provides a summary of the largest number of cases published, describing the specifics of this type of heart failure and attempting to explain why hypocalcaemic cardiomyopathy is so rare, even though hypocalcaemia is a frequent finding.

Case report 1 {#ehf212693-sec-0002}
=============

A 26‐year‐old woman was diagnosed with hypoparathyroidism in 2017 based on symptoms of paraesthesia and upper limb convulsions. Because of her limited intelligence, she was not taking any prescribed medication nor attending any physician\'s check‐ups. In May 2018, she was admitted to our hospital presenting with acute shortness of breath. The physical examination revealed short posture (158 cm), cachectic habitus, and heavily carious teeth (*Figure* [*1*](#ehf212693-fig-0001){ref-type="fig"}). Her blood pressure was 75/50 mmHg, and her heart rate was regular at 80 bpm. The electrocardiogram showed a sinus rhythm with QTc of 575 ms. Echocardiographic examination found a dilated left ventricle with a severely depressed EF of 25% because of diffuse hypokinesis. The LV diastolic function was also severely impaired. Only mild mitral and tricuspid regurgitations were present, and the estimated pulmonary artery systolic pressure was within the normal range. Cardiac magnetic resonance did not demonstrate any signs of myocardial inflammation or replacement fibrosis. The computed tomography coronary angiography was normal. Laboratory tests showed an unmeasurably high N terminal pro‐BNP level, as well as signs of renal and liver dysfunction. Importantly, advanced hypocalcaemia, hypomagnesaemia, and hyperphosphataemia were also found. Other possible causes of hypocalcaemia except hypoparathyroidism were not identified. An ophthalmologist\'s examination revealed an incipient cataract. Cerebral calcifications were not present on the computed tomography scan.

![The picture shows markedly carious dentition and dry peeling skin.](EHF2-7-1291-g001){#ehf212693-fig-0001}

Based on these findings, the diagnosis of acute heart failure because of the hypocalcaemic dilated cardiomyopathy associated with untreated hypoparathyroidism was made. The patient was treated with typical heart failure therapy together with calcitriol administration, and calcium and magnesium supplementation. At the end of the hospitalization, the patient was completely asymptomatic, and her blood ion levels were normal (*Table* [*1*](#ehf212693-tbl-0001){ref-type="table"}).

###### 

Patient 1 laboratory values

                                     May 2018 (admission)   May 2018 (discharge)   September 2018   November 2018 (admission)   November 2018 (discharge)   December 2019    Reference range
  ---------------------------------- ---------------------- ---------------------- ---------------- --------------------------- --------------------------- --------------- -----------------
  Calcium total (mmol/L)             1.19                   2.42                   1.23             1.21                        1.64                        0.99               2.00--2.75
  Calcium ionized (mmol/L)           0.64                   1.22                   0.62             0.60                        0.87                        0.56               1.13--1.32
  Phosphate (mmol/L)                 3.22                   1.7                    2.24             2.08                        2.16                        2.37               0.65--1.61
  Magnesium (mmol/L)                 0.53                   0.79                   0.41             0.35                        0.61                        0.35               0.70--1.00
  PTH (pmol/L)                       0.58                   0.58                   0.58             0.58                                                    0.58               1.58--6.03
  1,25‐OH vitamin D (ng/L)           6.2                                           14.4             14.4                        25.6                        33.2               19.9--79.3
  25‐OH vitamin D (ng/ml)            22.3                                          31.6             31.6                        32.3                        17.5               30.0--60.0
  NT‐proBNP (ng/L)                   \>35 000                                      807                                                                      2161                 0--125
  High sensitive troponin I (μg/L)   36.4                                          3.1              3.5                                                                          0--11.6
  CRP (mg/L)                         61.7                   1.1                    \<1.0            1.7                                                     3.3                   0--5
  Creatinin (μmol/L)                 279                    147                    92               99                          101                         91                   44--104
  Aspartate transaminase (ukat/L)    15.72                  0.22                   0.54             0.29                        \<0.2                       0.48               0.10--0.72
  Alanin transaminase (ukat/L)       22.22                  0.62                   0.29             \<0.1                       0.2                         0.21               0.10--0.72
  ScvO~2~ (%)                        46.3                   68.5                                                                                                            

1,25‐OH vitamin D, 1,25‐dihydroxycholecalciferol; 25‐OH vitamin D, 25‐hydroxycholecalciferol; CRP, C‐reactive protein; NT‐proBNP, N terminal pro brain natriuretic peptide; PTH, parathormone; ScvO~2~, central venous oxygen saturation.

In September 2018, the patient could tolerate exertion without restrictions, and the peeling, dry skin had disappeared. The LV systolic function was improved with an EF of 42%, as described by echocardiography. However, both the calcium and magnesium blood levels had decreased significantly (*Table* [*1*](#ehf212693-tbl-0001){ref-type="table"}). To rule out impaired absorption of the orally administered calcium and magnesium, the patient was admitted to the hospital, where peroral hypoparathyroidism treatment was administrated for 7 days. Importantly, she was not treated with heart failure medication at this time. During this short time period, there was a significant improvement and even normalization of hypocalcaemia, hypomagnesaemia, 1,25‐OH vitamin D level (*Table* [*1*](#ehf212693-tbl-0001){ref-type="table"}), LV systolic (*Figure* [*2*](#ehf212693-fig-0002){ref-type="fig"}), and diastolic (*Figure* [*3*](#ehf212693-fig-0003){ref-type="fig"}) function. Poor compliance with therapy was therefore presumed to be the cause of the non‐improving hypocalcaemia.

![The figure shows *M* mode tracings of the left ventricle that demonstrate significant improvement of left ventricular systolic function in November 2018 when the patient received oral treatment of hypoparathyroidism under supervision.](EHF2-7-1291-g002){#ehf212693-fig-0002}

![The figure depicts a noticeable increase of early diastolic septal mitral annular velocity (e′) in November 2018, reflecting the improvement in myocardial relaxation properties when the patient received oral treatment of hypoparathyroidism under supervision.](EHF2-7-1291-g003){#ehf212693-fig-0003}

At the end of 2019, the blood levels of calcium and magnesium had again decreased significantly. Similarly, LV systolic function had decreased (*Tables* [*1*](#ehf212693-tbl-0001){ref-type="table"} and [*2*](#ehf212693-tbl-0002){ref-type="table"}). The patient remains asymptomatic, but her long‐term prognosis is uncertain.

###### 

Patient 1 echocardiographic parameters

                            May 2018    June 2018   September 2018   November 2018 (admission)   November 2018 (discharge)   January 2019   December 2019
  ------------------------ ----------- ----------- ---------------- --------------------------- --------------------------- -------------- ---------------
  EDD (mm)                     55          55             50                    52                          50                    51             54
  EDD/BSA (mm/m^2^)            42          42             35                    37                          35                    36             38
  EDV (mL)                     130         102           115                    102                         102                   90             98
  EF (%)                       25          42             39                    43                          52                    48             33
  E (m/s)                      1.2         0.9           0.94                  0.93                        0.95                  0.96           0.75
  A (m/s)                     0.49         0.4           0.43                   0.5                        0.54                  0.38           0.58
  E/A ratio                   2.45        2.25           2.19                  1.86                        1.75                  2.53           1.29
  e′septal/lateral (m/s)    0.08/0.1    0.11/0.16     0.08/0.15              0.07/0.17                   0.12/0.19             0.09/0.2       0.08/0.13
  a′septal/lateral (m/s)    0.07/0.05   0.04/0.04     0.03/0.04              0.04/0.04                   0.04/0.05            0.04/0.05       0.04/0.05
  E/e′                        13.3         6.7           4.1                    7.8                         5,9                  6.6             8.0

BSA, body surface area; EDD, end diastolic diameter; EDV, end diastolic volume; EF, ejection fraction; ESD, end systolic diameter.

Case report 2 {#ehf212693-sec-0003}
=============

A 74‐year‐old man underwent a total thyroidectomy for goitre in 2009 and curative radiotherapy for prostate cancer in 2013. He was also treated for arterial hypertension and regularly followed‐up for stage 3 chronic kidney disease. A low plasma calcium level was also detected in 2014 by a urologist, but no treatment was administered.

In June 2017, the patient was admitted to hospital for several weeks\' lasting dyspnoea NYHA classes II and III. Both the blood pressure and heart rate were within the normal range. The electrocardiogram showed a sinus rhythm with a QTc interval of 450 ms. Echocardiographic examination demonstrated diffuse hypokinesis of non‐dilated LV with an EF of 44%. No significant valvular disease was present. A selective coronary angiography did not demonstrate any significant findings. The N terminal pro‐BNP level was significantly elevated. The laboratory examination also revealed hypocalcaemia and hyperphosphataemia because of primary hypoparathyroidism (*Table* [*3*](#ehf212693-tbl-0003){ref-type="table"}). The diagnosis of left‐sided heart failure because of hypocalcaemic dilated cardiomyopathy was established, and heart failure therapy as well as calcium supplementation were initiated.

###### 

Patient 2 laboratory values

                            July 2017   June 2018   September 2018   Reference range
  ------------------------ ----------- ----------- ---------------- -----------------
  Calcium total (mmol/L)      1.52        1.06           2.1           2.10--2.65
  Phosphate (mmol/L)           1.8         2.2           1.5            0.7--1.6
  Magnesium (mmol/L)          0.77         0.6                         0.70--1.07
  PTH (pmol/L)                  1                                       2.0--9.3
  NT‐proBNP (ng/L)            2052       22 000                          0--450
  Creatinine (μmol/L)          126         181           130             64--104
  Albumin (g/L)                47                                        35--53
  TSH (mU/L)                   1.2        1.57                         0.55--4.78
  fT~4~ (pmol/L)              20.7        21.7                         11.5--22.7

CRP, C‐reactive protein; fT~4~, free thyroxine; NT‐proBNP, N terminal pro brain natriuretic peptide; PTH, parathormone; TSH, thyroid‐stimulating hormone.

However, the patient arbitrarily stopped taking the medication and was repeatedly hospitalized for heart failure decompensation during the following months. A severe decrease in LV systolic function with EF of 26% was found (*Table* [*4*](#ehf212693-tbl-0004){ref-type="table"}). The status was further complicated by an acute kidney injury requiring acute haemodialysis in June 2018. At that time, both the hypocalcaemia and hyperphosphataemia worsened, and hypomagnesaemia was also diagnosed (*Table* [*3*](#ehf212693-tbl-0003){ref-type="table"}). The treatment of hypoparathyroidism was restored, with resulting improvement of the patient\'s condition in a few days. At the 3 month follow‐up, in September 2018, the patient did not report any heart failure symptoms. He declared having taken all of the prescribed medication targeting hypoparathyroidism and heart failure. Laboratory values of calcium phosphate metabolism were within the normal range, and echocardiographic examination demonstrated significant improvement in the LV systolic function with an EF of 52% (*Table* [*4*](#ehf212693-tbl-0004){ref-type="table"}).

###### 

Patient 2 echocardiographic parameters

                                                    June 2018   September 2018
  ------------------------------------------------ ----------- ----------------
  EDD (mm)                                             63             58
  ESD (mm)                                             52             42
  EDV (mL)                                             201     
  Left ventricular ejection fraction (%)               26             52
  Right ventricular end‐diastolic dimension (mm)       46             34
  Right atrial area (cm^2^)                           31.1           26.5
  Mitral regurgitation, grade (1--4)                  2--3            2
  Tricuspid regurgitation peak gradient (mmHg)         40             23

BSA, body surface area; EDD, end diastolic diameter; EDV, end diastolic volume; EF, ejection fraction; ESD, end systolic diameter.

Summary of current literature on hypocalcaemic cardiomyopathy {#ehf212693-sec-0004}
-------------------------------------------------------------

The PubMed database was searched in November 2019 using the keywords 'hypocalcemia AND cardiomyopathy' and 'hypocalcemia AND heart failure', as well as using references found in the articles. Only articles in English were included, with the exception of the first published case, which was published in German. The reports on patients \< 18 years were excluded. Only symptomatic heart failure cases were included in the evaluation. Our two cases were also included in the overall evaluation. A total of 57 articles describing 61 cases were found.[^2^](#ehf212693-bib-0002){ref-type="ref"}, [^3^](#ehf212693-bib-0003){ref-type="ref"}, [^4^](#ehf212693-bib-0004){ref-type="ref"}, [^5^](#ehf212693-bib-0005){ref-type="ref"}, [^6^](#ehf212693-bib-0006){ref-type="ref"}, [^7^](#ehf212693-bib-0007){ref-type="ref"}, [^8^](#ehf212693-bib-0008){ref-type="ref"}, [^9^](#ehf212693-bib-0009){ref-type="ref"}, [^10^](#ehf212693-bib-0010){ref-type="ref"}, [^11^](#ehf212693-bib-0011){ref-type="ref"}, [^12^](#ehf212693-bib-0012){ref-type="ref"}, [^13^](#ehf212693-bib-0013){ref-type="ref"}, [^14^](#ehf212693-bib-0014){ref-type="ref"}, [^15^](#ehf212693-bib-0015){ref-type="ref"}, [^16^](#ehf212693-bib-0016){ref-type="ref"}, [^17^](#ehf212693-bib-0017){ref-type="ref"}, [^18^](#ehf212693-bib-0018){ref-type="ref"}, [^19^](#ehf212693-bib-0019){ref-type="ref"}, [^20^](#ehf212693-bib-0020){ref-type="ref"}, [^21^](#ehf212693-bib-0021){ref-type="ref"}, [^22^](#ehf212693-bib-0022){ref-type="ref"}, [^23^](#ehf212693-bib-0023){ref-type="ref"}, [^24^](#ehf212693-bib-0024){ref-type="ref"}, [^25^](#ehf212693-bib-0025){ref-type="ref"}, [^26^](#ehf212693-bib-0026){ref-type="ref"}, [^27^](#ehf212693-bib-0027){ref-type="ref"}, [^28^](#ehf212693-bib-0028){ref-type="ref"}, [^29^](#ehf212693-bib-0029){ref-type="ref"}, [^30^](#ehf212693-bib-0030){ref-type="ref"}, [^31^](#ehf212693-bib-0031){ref-type="ref"}, [^32^](#ehf212693-bib-0032){ref-type="ref"}, [^33^](#ehf212693-bib-0033){ref-type="ref"}, [^34^](#ehf212693-bib-0034){ref-type="ref"}, [^35^](#ehf212693-bib-0035){ref-type="ref"}, [^36^](#ehf212693-bib-0036){ref-type="ref"}, [^37^](#ehf212693-bib-0037){ref-type="ref"}, [^38^](#ehf212693-bib-0038){ref-type="ref"}, [^39^](#ehf212693-bib-0039){ref-type="ref"}, [^40^](#ehf212693-bib-0040){ref-type="ref"}, [^41^](#ehf212693-bib-0041){ref-type="ref"}, [^42^](#ehf212693-bib-0042){ref-type="ref"}, [^43^](#ehf212693-bib-0043){ref-type="ref"}, [^44^](#ehf212693-bib-0044){ref-type="ref"}, [^45^](#ehf212693-bib-0045){ref-type="ref"}, [^46^](#ehf212693-bib-0046){ref-type="ref"}, [^47^](#ehf212693-bib-0047){ref-type="ref"}, [^48^](#ehf212693-bib-0048){ref-type="ref"}, [^49^](#ehf212693-bib-0049){ref-type="ref"}, [^50^](#ehf212693-bib-0050){ref-type="ref"}, [^51^](#ehf212693-bib-0051){ref-type="ref"}, [^52^](#ehf212693-bib-0052){ref-type="ref"}, [^53^](#ehf212693-bib-0053){ref-type="ref"}, [^54^](#ehf212693-bib-0054){ref-type="ref"}, [^55^](#ehf212693-bib-0055){ref-type="ref"}, [^56^](#ehf212693-bib-0056){ref-type="ref"}, [^57^](#ehf212693-bib-0057){ref-type="ref"}, [^58^](#ehf212693-bib-0058){ref-type="ref"} All publications were independently evaluated by two researchers (M. V. and L. R.).

Heart failure was divided according to the *Guidelines of the European Society of Cardiology* for heart failure with reduced EF (EF \< 40%; HFrEF), mid‐range EF (EF 40--49%; HFmrEF), and preserved EF (EF ≥ 50%).[^59^](#ehf212693-bib-0059){ref-type="ref"} The improvement of the LV systolic function was defined as an absolute increase ≥10% (i.e. 10 percentage points) in the LVEF[^60^](#ehf212693-bib-0060){ref-type="ref"} or as an improvement of the LVEF ≥ 50%. Only publications that stated the baseline LVEF numerically (*n* = 39) were included in the evaluation of the initial heart failure type. Those publications reporting both the baseline and final LVEF numerically (*n* = 33) or verbally indicated EF improvement/normalization (*n* = 4) were included in the outcome evaluation. Several methods (echocardiography, invasive ventriculography, and scintigraphy) were used for the evaluation of LVEF in the literature reviewed. LV diastolic function, right ventricular function, and other echocardiographic parameters were only sporadically reported in the published articles and thus not completely evaluated in our review.

Discussion {#ehf212693-sec-0005}
==========

The first case report of hypocalcaemic cardiomyopathy was described in 1939 by Hegglin[^38^](#ehf212693-bib-0038){ref-type="ref"} of a 51‐year‐old female patient with a history of goitre surgery and presenting with congestive heart failure. The sole administration of dihydrotachysterol (AT 10) resulted in an improvement of diuresis as well as symptom relief.

Hypocalcaemic cardiomyopathy is considered to be a rare disease. To our best knowledge, 61 cases have been described so far. The basic characteristics of these patients, as well as our cases, are summarized in *Table* [*5*](#ehf212693-tbl-0005){ref-type="table"}. The described cases of hypocalcaemic cardiomyopathy show a slight predilection for the female gender (62%). The mean age of the affected patients is 48.3 years.

###### 

Summarization of the basic characteristics of cases described in literature from 1939 to November 2019

  Author                       Journal                         Year   Age (years)   Sex      Aetiology of hypocalcaemia             Hypocalcaemia duration                                          Arrhythmia/ECG changes
  ---------------------------- ------------------------------- ------ ------------- -------- -------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------------
  Hegglin                      *Helvetica Medica Acta*         1939   51            Female   Thyreoidectomy                         25 years                                                        
  Evans                        *Lahey Clin Bull*               1945   43            Male     Primary hyperparathyroidism            Unknown                                                         
  Jernigan                     *Stanford Med Bull*             1953   58            Female   Primary hyperparathyroidism            27 years                                                        Premature ventricular contractions
  Grieve                       *SA Medical J*                  1955   38            Female   Primary hyperparathyroidism            3 years                                                         Long QT
  Sussman                      *NEJM*                          1957   52            Male     Primary hyperparathyroidism            Unknown                                                         Long QT
  Falko                        *Am J Med Sci*                  1976   19            Male     Primary hyperparathyroidism            10 days                                                         
  Brenton                      *Postgrad Med J*                1978   35            Male     Primary hyperparathyroidism            Unknown                                                         Long QT
  Bashour                      *Chest*                         1980   35            Female   Idiopathic hypocalcaemia               At least 7 years                                                Long QT
  Murros                       *Acta Med Scand*                1980   18            Female   Thyreoidectomy                         1.5 years                                                       Incessant polymorphic ventricular tachycardia
  Giles                        *Chest*                         1981   47            Female   Thyreoidectomy                         5 years                                                         Long QT
  Connor                       *NEJM*                          1982   76            Female   Primary hyperparathyroidism            9 months                                                        
  Levine                       *Am J Med*                      1985   39            Female   Thyreoidectomy                         10 years                                                        Long QT
  Rimailho                     *Am Heart J*                    1985   61            Male     Primary hyperparathyroidism            Unknown                                                         
  Varthakavi                   *In Heart J*                    1985   44            Female   Parathyreoidectomy                     3 days                                                          Long QT
  Huddle                       *SAMJ*                          1987   39            Female   Primary hyperparathyroidism            9 years                                                         Long QT
  Huddle                       *SAMJ*                          1987   58            Female   Primary hyperparathyroidism            Unknown                                                         Long QT
  Huddle                       *SAMJ*                          1987   38            Female   Unknown                                At least 6 months                                               Long QT
  Csanády                      *Br Heart J*                    1990   25            Female   Primary hyperparathyroidism            Unknown                                                         Long QT
  Mano                         *Jpn J Med*                     1991   65            Female   Primary hyperparathyroidism            Unknown                                                         
  Kudoh                        *Int Med*                       1992   46            Male     Primary hyperparathyroidism            At least 20 years                                               Non‐sustained ventricular tachycardia, atrial fibrillation, long QT
  Shinoda                      *Nephron*                       1992   60            Male     Parathyroidectomy                      1 day                                                           
  Rallidis                     *Int J Cardiol*                 1997   46            Female   Primary hyperparathyroidism            At least 2 years                                                Long QT
  Suzuki                       *Clin Cardiol*                  1997   53            Female   Primary hyperparathyroidism            At least 10 years                                               Long QT
  Lehmann                      *Chest*                         2000   25            Female   Primary hyperparathyroidism            At least 1.5 years                                              Long QT
  Fisher                       *Eur J Heart Failure*           2001   38            Male     Parathyreoidectomy                     3 weeks                                                         
  Nasser                       *CHF*                           2001   55            Male     Primary hyperparathyroidism            3 years                                                         Long QT
  Altunbas                     *Horm Res*                      2002   46            Female   Thyreoidectomy                         12 years (treated only in symptomatic hypocalcaemic episodes)   
  Altunbas                     *Horm Res*                      2003   55            Male     Thyreoidectomy                         19 years (treated only in symptomatic hypocalcaemic episodes)   Atrial fibrillation, long QT
  Avsar                        *Echocardiography*              2004   40            Female   Thyreoidectomy                         3 years                                                         Junctional tachycardia, long QT
  Hurley                       *J Emerg Med*                   2005   73            Male     Primary hyperparathyroidism            Unknown                                                         Long QT
  Tsironi                      *Int J Hematology*              2005   25            Male     Hemosiderosis‐beta‐thalassemia         Unknown                                                         Atrial fibrillation, long QT
  Tziomalos                    *Clin Endocrin*                 2006   68            Male     Primary hyperparathyroidism            Unknown                                                         Atrial fibrillation, long QT
  Gupta                        *JAPI*                          2007   18            Male     Primary hyperparathyroidism            Unknown                                                         Long QT
  Chavan                       *Annals Int Med*                2007   48            Male     Vitamin D deficiency                   Unknown                                                         Monomorphic and polymorphic ventricular tachycardia, long QT
  Kazmi                        *Am J Med Sci*                  2007   71            Female   Thyreoidectomy                         4 years                                                         Long QT
  Broncel                      *Arch Med Sci*                  2010   60            Female   Primary hyperparathyroidism            Unknown                                                         Long QT
  Jariwala                     *JAPI*                          2010   24            Male     Primary hyperparathyroidism            Unknown                                                         Long QT
  Lekas                        *Adv Perit Dial*                2010   27            Female   Parathyreoidectomy                     8 months                                                        Long QT
  Mavroudis                    *Clin Cardiol*                  2010   39            Male     Hypoparathyreosis‐coeliac disease      Unknown                                                         Long QT
  Solzbach                     *Herz*                          2010   61            Male     Thyreoidectomy                         6 months                                                        Long QT
  Sung                         *J Cardiovasc Ultrasound*       2010   57            Female   Primary hyperparathyroidism            Unknown                                                         
  Babu                         *Indian J Endocrinol Metab*     2011   70            Female   Primary hyperparathyroidism            Unknown                                                         Long QT
  Behaghel                     *Eur J Echocar*                 2011   76            Female   Thyreoidectomy                         25 years                                                        Long QT
  Ballane                      *Eur J Endokrin*                2012   56            Female   Thyreoidectomy                         21 years                                                        
  Ipek                         *Herz*                          2013   24            Female   Thyreoidectomy                         1 year                                                          
  Jung                         *Korean J Intern Med*           2013   50            Female   Primary hyperparathyroidism            Unknown                                                         Long QT
  Rhee                         *Korean Circul J*               2013   69            Female   Primary hyperparathyroidism            5 years                                                         Long QT
  Bansal                       *J Clin Endocrinol Metab*       2014   47            Female   Primary hyperparathyroidism            5 years                                                         Long QT
  Jeong                        *Endocrinol Metab*              2014   29            Female   Hemosiderosis                          10 years                                                        
  Vlot                         *BMJ Case rep*                  2014   59            Female   Primary hyperparathyroidism            Unknown                                                         
  Vlot                         *BMJ Case rep*                  2014   68            Female   Thyreoidectomy                         Unknown                                                         
  Jamieson                     *J R Coll Phisicians Edinb*     2015   45            Male     Digeorge syndrome ‐22q11.21 deletion   5 years                                                         
  Venugopalan                  *JAGS*                          2015   87            Male     Vitamin D deficiency                   Unknown                                                         Ventricular tachycardia
  Batra                        *J Ass Physicians India*        2016   68            Female   Vitamin D deficiency                   Unknown                                                         Long QT
  Elikowski                    *Pol Merkur Lekarski*           2017   60            Male     Thyreoidectomy                         36 years                                                        Long QT
  Andreozzi                    *Eur J Case Rep Intern Med*     2018   56            Female   Unknown                                Unknown                                                         Long QT
  Kadeli                       *J Assoc Physicians India*      2018   34            Female   Thyreoidectomy                         5 years                                                         Long QT
  de Oliveira Martins Duarte   *Clinical Case Reports*         2019   54            Female   Primary hyperparathyroidism            Unknown                                                         
  Fasih                        *Eur J Case Rep 12Intern Med*   2019   22            Male     Pseudohypoparathyroidism               At least 5 years                                                
  Parepa                       *Acta Endocrinologica (Buc)*    2019   40            Female   Thyreoidectomy                         6 years                                                         Long QT
  Saini                        *BMJ Case Rep*                  2019   55            Male     Primary hyperparathyroidism            Unknown                                                         Long QT
  Schaffelhoferová             *Cor Vasa*                      2019   74            Male     Thyreoidectomy                         8 years                                                         
  Válek                        ESC Heart Failure               2020   26            Female   Primary hyperparathyroidism            Unknown                                                         Long QT

ECG, echocardiogram.

Aetiology {#ehf212693-sec-0006}
---------

The rareness of hypocalcaemic cardiomyopathy is surprising because hypoparathyroidism and hypocalcaemia are much more frequent. The prevalence of hypocalcaemia because of hypoparathyroidism in adults is reported to be 20--40 cases per 100 000 people.[^61^](#ehf212693-bib-0061){ref-type="ref"}, [^62^](#ehf212693-bib-0062){ref-type="ref"}, [^63^](#ehf212693-bib-0063){ref-type="ref"} Previous studies have considered a possible explanation of hypocalcaemic cardiomyopathy being a late manifestation of long‐lasting hypocalcaemia.[^2^](#ehf212693-bib-0002){ref-type="ref"}, [^30^](#ehf212693-bib-0030){ref-type="ref"} In most patients, the symptoms of hypocalcaemia that would lead to treatment initiation would probably have appeared earlier. This hypothesis is supported by data from the collected case reports. In primary hypoparathyroidism, it is difficult to determine the exact duration of hypocalcaemia. However, in patients after surgery, the interval between surgery and the development of hypocalcaemic cardiomyopathy can be easily ascertained. In a subgroup of 16 individuals with a history of thyroidectomy, the median time for the development of hypocalcaemic cardiomyopathy was 10 years, with a range of 1.5 months to 36 years.

Generally, the most common cause of hypoparathyroidism is the post‐thyroidectomy condition that makes up 80--90% of cases.[^61^](#ehf212693-bib-0061){ref-type="ref"}, [^62^](#ehf212693-bib-0062){ref-type="ref"}, [^63^](#ehf212693-bib-0063){ref-type="ref"}, [^64^](#ehf212693-bib-0064){ref-type="ref"} Interestingly, the development of hypocalcaemic cardiomyopathy is most commonly related to idiopathic hypoparathyroidism (*Figure* [*4*](#ehf212693-fig-0004){ref-type="fig"}). As idiopathic hypoparathyroidism is difficult to diagnose and patients after thyroidectomy receive regular check‐ups, hypocalcaemia in idiopathic hypoparathyroidism may take longer to be diagnosed.

![The aetiology of the majority of cases of hypocalcaemic cardiomyopathy is hypoparathyroidism, as shown on the left side of the figure. The right side depicts causes of hypoparathyroidism and shows that primary hypoparathyroidism represents most cases.](EHF2-7-1291-g004){#ehf212693-fig-0004}

In some patients, symptoms of hypocalcaemia do not appear for reasons that are unclear. However, some individuals have unrecognized symptoms of hypocalcaemia. A few patients had been erroneously diagnosed with epilepsy or epileptiform seizures.[^10^](#ehf212693-bib-0010){ref-type="ref"}, [^11^](#ehf212693-bib-0011){ref-type="ref"}, [^21^](#ehf212693-bib-0021){ref-type="ref"}, [^25^](#ehf212693-bib-0025){ref-type="ref"} Some patients were also insufficiently treated, or they showed poor cooperation.[^2^](#ehf212693-bib-0002){ref-type="ref"}, [^21^](#ehf212693-bib-0021){ref-type="ref"}, [^42^](#ehf212693-bib-0042){ref-type="ref"}, [^46^](#ehf212693-bib-0046){ref-type="ref"}

Pathophysiology {#ehf212693-sec-0007}
---------------

The exact pathophysiology of hypocalcaemic cardiomyopathy has not been yet clarified. The lack of calcium is not the only mechanism that leads to the development of heart failure, although its low levels play a key role. Intracellular changes in calcium concentrations are essential for myocyte activity, as the transfer of calcium from the extracellular into the intracellular space triggers a chain reaction that ends in myocyte contraction. The increase of intracellular calcium concentration transiting through calcium channels is followed by calcium release from sarcoplasmic reticulum, its binding to the troponin--tropomyosin complex, and stimulation of the mutual binding of actin and myosin.[^65^](#ehf212693-bib-0065){ref-type="ref"} Additionally, in contrast to striated myocytes, the activity of cardiac myocytes is directly dependent on the calcium concentration in the extracellular fluid.[^66^](#ehf212693-bib-0066){ref-type="ref"}

Vitamin D deficiency may have a direct effect on the development of myocardial dysfunction. In rat experiments, vitamin D deficiency was associated with the development of cardiac hypertrophy and fibrosis.[^67^](#ehf212693-bib-0067){ref-type="ref"} The mechanism leading to the described changes consists of decreased renin production and the subsequent increased activity of the renin--angiotensin system.[^68^](#ehf212693-bib-0068){ref-type="ref"}, [^69^](#ehf212693-bib-0069){ref-type="ref"} Epidemiological studies in humans have shown that low levels of vitamin D are linked to LV systolic dysfunction, a higher risk of developing heart failure, increased mortality, and sudden death.[^70^](#ehf212693-bib-0070){ref-type="ref"}, [^71^](#ehf212693-bib-0071){ref-type="ref"}, [^72^](#ehf212693-bib-0072){ref-type="ref"}

Parathormone (PTH) has an independent apparent influence as it directly affects the [l]{.smallcaps}‐calcium ion channels in the myocardium and also has a positive chronotropic effect in neonatal cells.[^73^](#ehf212693-bib-0073){ref-type="ref"}

Magnesium also plays a role in the pathophysiology of calcium and phosphate metabolism. Its low levels are often observed in patients with hypocalcaemic cardiomyopathy. Magnesium contributes to the regulation of PTH secretion. Mild hypomagnesaemia stimulates PTH secretion, but severely low levels of magnesium (\<0.5 mmol/L) are associated with a paradoxical block of PTH secretion.[^74^](#ehf212693-bib-0074){ref-type="ref"}, [^75^](#ehf212693-bib-0075){ref-type="ref"} Based on this mechanism, pronounced hypomagnesaemia could be one of the causes of hypoparathyroidism resistant to the administration of calcium. Nevertheless, magnesium supplementation leads to an increase of PTH within a few minutes.[^75^](#ehf212693-bib-0075){ref-type="ref"} In the published case reports, 41% of the patients had low plasma levels of magnesium (\<0.7 mmol/L), but only two patients, described in [Case Report 1](#ehf212693-sec-0002){ref-type="sec"} and by Andreozzi *et al.,* [^52^](#ehf212693-bib-0052){ref-type="ref"} reached a value below 0.5 mmol/L. However, even after the supplementation of magnesium level to normal values, the PTH level did not increase in our Case 1 and thus the hypoparathyroidism appears unlikely to have been caused by severe hypomagnesaemia in this particular patient. Only in Andreozzi\'s case was the hypocalcaemia possibly secondary to hypomagnesaemia.

Generally, low levels of plasma magnesium are considered to be one of the risk factors for the development of heart failure.[^76^](#ehf212693-bib-0076){ref-type="ref"}, [^77^](#ehf212693-bib-0077){ref-type="ref"}, [^78^](#ehf212693-bib-0078){ref-type="ref"} Hypomagnesaemia may therefore be an additional risk factor involved in heart failure exacerbation in patients with hypocalcaemic cardiomyopathy.

Other manifestations of hypoparathyroidism/hypocalcaemia {#ehf212693-sec-0008}
--------------------------------------------------------

Patients with hypocalcaemic cardiomyopathy have manifestations of hypoparathyroidism and/or hypocalcaemia, which are summarized in *Table* [*6*](#ehf212693-tbl-0006){ref-type="table"}. The most commonly described complications are cerebral calcifications (12 patients), cognitive deficit (11 patients), and cataracts (12 patients).

###### 

Hypoparathyroidism complications. In addition to complications common to hypoparathyroidism, it is worth noting that four patients were misdiagnosed with epilepsy attributed to hypocalcaemic convulsions

                          Patients (*N*)
  ----------------------- ----------------
  Brain calcifications    12
  Cataract                12
  Cognitive dysfunction   11
  Teeth destruction       3
  'Epilepsy'              4

The often‐occurring cognitive deficit or reduced intelligence is particularly important. Apart from the fact that it is probably another manifestation of prolonged hypoparathyroidism,[^79^](#ehf212693-bib-0079){ref-type="ref"}, [^80^](#ehf212693-bib-0080){ref-type="ref"} it is a factor that can significantly delay the patient\'s diagnosis, as well as impair their cooperation in the treatment.

Manifestation of hypocalcaemic cardiomyopathy {#ehf212693-sec-0009}
---------------------------------------------

Based on our literature review, hypocalcaemic cardiomyopathy predominantly leads to HFrEF (in 87% so far described cases), while 11% of patients suffered from HFmrEF,[^2^](#ehf212693-bib-0002){ref-type="ref"}, [^8^](#ehf212693-bib-0008){ref-type="ref"}, [^11^](#ehf212693-bib-0011){ref-type="ref"}, [^17^](#ehf212693-bib-0017){ref-type="ref"}, [^32^](#ehf212693-bib-0032){ref-type="ref"} and only one individual had heart failure with preserved EF.[^34^](#ehf212693-bib-0034){ref-type="ref"} Both HFrEF and HFmrEF manifested in 83% of cases as diffuse LV hypokinesia. Regional wall motion abnormalities were described in 10% of individuals, and in two cases, the LV kinetics resembled Takotsubo cardiomyopathy.[^40^](#ehf212693-bib-0040){ref-type="ref"}, [^52^](#ehf212693-bib-0052){ref-type="ref"}

The published articles only sporadically described the influence of hypocalcaemia on LV diastolic properties. [Case Report 1](#ehf212693-sec-0002){ref-type="sec"}, in accordance with another article,[^5^](#ehf212693-bib-0005){ref-type="ref"} shows that hypocalcaemia may be associated with significant LV diastolic dysfunction, which may be dramatically improved or even completely normalized with the appropriate therapy (*Table* [*2*](#ehf212693-tbl-0002){ref-type="table"}; *Figure* [*2*](#ehf212693-fig-0002){ref-type="fig"}).

In addition to symptoms of heart failure, hypocalcaemic cardiomyopathy may also manifest with arrhythmias. Atrial fibrillation was documented in three patients, sustained or non‐sustained monomorphic and polymorphic ventricular tachycardia in four subjects, ventricular extrasystoles in one individual, and junctional tachycardia in one patient.[^2^](#ehf212693-bib-0002){ref-type="ref"}, [^3^](#ehf212693-bib-0003){ref-type="ref"}, [^23^](#ehf212693-bib-0023){ref-type="ref"}, [^28^](#ehf212693-bib-0028){ref-type="ref"}, [^30^](#ehf212693-bib-0030){ref-type="ref"}, [^37^](#ehf212693-bib-0037){ref-type="ref"}, [^49^](#ehf212693-bib-0049){ref-type="ref"}

Prognosis {#ehf212693-sec-0010}
---------

The prognosis of hypocalcaemic cardiomyopathy, if treated, is good. In almost three quarters of patients reported so far, the normalization of LV systolic function was noted, and in a further 21% of individuals, a significant improvement of the LVEF occurred. The LV systolic function remained unimproved in only 5% of patients. [Case Report 1](#ehf212693-sec-0002){ref-type="sec"} nicely shows that improvement in the LVEF can occur within a few days after plasma calcium level normalization. A rapid improvement of LV systolic properties was also described by Wong *et al*.[^81^](#ehf212693-bib-0081){ref-type="ref"} in a series of six asymptomatic hypocalcaemic patients who experienced a significant increase in cardiac output after a 1 h long calcium infusion. There may be multiple reasons for the lack of improvement in LV systolic function in a minority of patients. In addition to poor cooperation of the patient, cardiomyocyte degeneration and the development of myocardial fibrosis may also play an important role.[^2^](#ehf212693-bib-0002){ref-type="ref"}

As shown in [Case Report 1](#ehf212693-sec-0002){ref-type="sec"}, the improvement of LV systolic function may be achieved solely by the normalization of calcium and phosphate metabolism, without the administration of conventional heart failure medication. In cases of hypoparathyroidism, this treatment should not be limited to calcium supplementation, which has only a short‐term effect, but should also include calcitriol therapy. Treatment with recombinant PTH represents an alternative to calcitriol in case of its insufficient effect.[^5^](#ehf212693-bib-0005){ref-type="ref"}, [^82^](#ehf212693-bib-0082){ref-type="ref"} Nevertheless, heart failure therapy is regularly administered in affected patients according to the current guidelines.

So far, only two fatal cases of hypocalcaemic cardiomyopathy have been described.[^12^](#ehf212693-bib-0012){ref-type="ref"} A 76‐year‐old patient with cognitive deficiency was repeatedly hospitalized for decompensated heart failure. His plasma calcium level could not be compensated, and both dementia as well as cachexia progressed fatally. Another fatal case possibly related to hypocalcaemic cardiomyopathy is that of a 16 years old who died because of an unexplained heart failure and who was the sister of a patient with known idiopathic hypoparathyroidism.[^13^](#ehf212693-bib-0013){ref-type="ref"} There is no evidence that she suffered from hypocalcaemia, but death because of heart failure at such a young age is very rare. Therefore, it can be hypothesized that they both shared a hereditary form of primary hypoparathyroidism that was recognized in only one sibling.

Conclusions {#ehf212693-sec-0011}
===========

Hypocalcaemic cardiomyopathy is a rare but treatable cause of heart failure with a good prognosis when diagnosed properly. Plasma calcium and magnesium levels and eventually vitamin D level testing should therefore become a routine examination for all patients with unexplained heart failure.
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